Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp alfa with or without pembrolizumab in advanced solid tumors and melanoma
NCT04157517Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, open-label trial of modakafusp alfa in Neoplasm and melanoma (5 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Treatment-emergent Adverse Events, Grade 3 or Higher Treatment-emergent Adverse Events and 4 more. Started Dec 2019; status: terminated.
02
Drugs
modakafusp alfa
03
Conditions
Neoplasmmelanoma
Beyond the preview
Go deeper on NCT04157517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157517.